Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01857518
Other study ID # 2012-A01466-37
Secondary ID D500
Status Recruiting
Phase N/A
First received May 16, 2013
Last updated October 18, 2017
Start date August 31, 2013
Est. completion date March 2018

Study information

Verified date October 2017
Source Centre Hospitalier St Anne
Contact Marie-Laure PAILLERE-MARTINOT, MD, PhD
Phone +33158412426
Email ml.paillere@cch.aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Adolescence is a critical period for the development of depressive disorders. As adolescence also is a critical period for brain maturation, it may be hypothesized that maturation changes in emotional circuits could underlie vulnerability for depression.

The aims of the study are (1) to identify the changes in brain morphometry, white matter microstructure, and functioning, in networks associated with depression features in adolescents, and (2) to assess the effects of treated pathology on brain structure by comparing the neuroimaging measures obtained in adolescents at inclusion with those at follow-up.


Description:

Adolescence is a key development period for neurobiological processes underlying emotional and cognitive functions in adulthood. The pathophysiology of mood disorders has recently been associated with maturation changes in brain networks, but little is known on the early brain structure changes associated with depression appearing during this major brain maturation period.

The hypothesis of altered structural integrity of limbic prefrontal pathways emerges from the literature on depression, but it is unknown whether it is also detectable in adolescents with depression. Thus, we aim to investigate WM and GM structure and anatomy, and functional correlates of behavioral responses in depressed adolescents.

40 adolescents with a Major Depressive Episode will be investigated using structural T1 magnetic-resonance imaging and diffusion tensor imaging (DTI), at inclusion and after one-year follow-up. Additionally, they will be investigated with fMRI.

Covariation patterns between neuroimaging and behavioural/clinical variables will be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date March 2018
Est. primary completion date February 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 18 Years
Eligibility Inclusion Criteria:

Depressed adolescents:

Teenagers of both sexes, from 15 to 18 years old, without contreindications in magnetic fields

- affiliation to a Social insurance

- Informed consent signed by the holders of the parental rights (a specific information note to the teenager)

- Diagnosis DSM-IV-TR ( 2000 ) of depressive Disorder of the humor without psychotic characteristics. The symptoms will have to be persistent for 3 weeks, in spite of a coverage of support ( 2 consultations).

Exclusion Criteria:

- Ferromagnetical Material in the body

- Claustrophobia, Syndrom of post-traumatic stress, Obsessive-compulsive Disorder, Disturb Tricks, Disturbs abuse of substances

- Intrusive disorder of the development, Disturbs hyperactivity deficit of the attention, Disorders of the conducts, Schizophrenia

- Current antidepressant or antipsychotic psychotropic Treatment for more than 15 days in effective doses

- Current somatic pathology, or pregnancy (urinary test of pregnancy in case of doubt)

- Histories of cranial trauma or neurological pathology, or of lower born weight in 800g

- History of electroconvulsivotherapy in the previous 6 months

- Refusal to give his(her) consent or to be revised on one year after inclusion

Healthy adolescents: will be screened to be matched to the patients according to age and sex. They will have no psychiatric diagnosis, and no family history of psychiatric conditions.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI
Visit V1: Diagnostic and clinical assessments Visit V2: psycho-behavioral assessment and neuroimaging Visit V3: Diagnostic and clinical assessments Visit V4: psycho-behavioral assessment and neuroimaging

Locations

Country Name City State
France Cochin Hospital Paris

Sponsors (5)

Lead Sponsor Collaborator
Centre Hospitalier St Anne Assistance Publique - Hôpitaux de Paris, CENIR Centre de Neuroimagerie de Recherche, Paris, Inserm CEA Research unit U1000 (Neuroimaging in psychiatry), National Research Agency, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evidence of white matter microstructure changes Statistical map of voxel-based analysis of white matter using tract based spatial statistics (TBSS) to compare depressed adolescents and healthy controls in emotional and reward networks Baseline
Primary Evidence of grey matter volume changes Statistical map of voxel-based analysis of grey matter using statistical parametric mapping (SPM8) to compare depressed adolescents and healthy controls in emotional and reward networks Baseline
Secondary Correlation between Functional anatomy of emotional/reward responses and white matter and grey matter structure changes Baseline
Secondary Grey matter and white matter changes in frontal limbic networks at follow-up in treated patients Follow-up one year
See also
  Status Clinical Trial Phase
Completed NCT00399776 - Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy N/A
Completed NCT04603053 - Determining Effectiveness of an mHealth Intervention to Provide Adolescent CBT N/A
Completed NCT01802437 - An Adaptive Treatment Strategy for Adolescent Depression Phase 1/Phase 2
Completed NCT06325605 - Efficacy and Safety of Bifidobacterium Combined With High-frequency Transcranial Magnetic Stimulation in the Treatment of Adolescent Depression N/A
Completed NCT02017535 - An Adaptive Treatment Strategy for Adolescent Depression-Continuation Phase 1/Phase 2
Completed NCT03154008 - Predictors of Response to Treatment for Depression N/A
Recruiting NCT04613453 - Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine Phase 2
Terminated NCT00284791 - Lamotrigine in Treatment Resistant Depression in Adolescents N/A
Completed NCT00312897 - Omega-3 Fatty Acids in Adolescent Depression Phase 2
Recruiting NCT06072677 - Adolescent Mood During Puberty and Testosterone N/A
Recruiting NCT01170520 - Repetitive Transcranial Stimulation (rTMS) for Resistant Depression in Adolescents Phase 1/Phase 2